Gastroenterology Research and Practice / 2017 / Article / Tab 1 / Review Article
A Meta-Analysis and Systematic Review of the Efficacy of Twice Daily PPIs versus Once Daily for Treatment of Gastroesophageal Reflux Disease Table 1 Baseline characteristics of the 7 randomized controlled trials included in this meta-analysis comparing the treatment effects of PPIs once daily versus twice daily for GERD patients.
Author Country Participants Duration Age (mean or mean ± SD, y) Male (%) Weight (kg) or BMI Intervention Orlando et al. 2010 USA 368 4 weeks 43.7 46.3% 29.2 Esomeprazole 20 mg QD 43.9 42.1% 29.8 Esomeprazole 40 mg QD 46.9 38.1% 30.5 Esomeprazole 40 mg BID Delchier et al. 2000 Europe 310 8 weeks 55 ± 15.7 55% N Rabeprazole 20 mg QD 52 ± 14.3 70% N Rabeprazole 10 mg BID 53 ± 15.1 61% N Omeprazole 20 mg QD Fass et al. 2006 USA 328 8 weeks 49 ± 12.5 40.6% 86.9 ± 19.7 Esomeprazole 40 mg QD 48.3 ± 13.6 45.8% 87.5 ± 19.2 Lansoprazole 30 mg BID Kinoshita and Hongo 2012 Japan 337 8 weeks 64.5 ± 13.9 51.8% 24.14 ± 3.61 Rabeprazole 20 mg QD 65.5 ± 13.3 46.8% 24.89 ± 3.68 Rabeprazole 10 mg BID 66.6 ± 13.8 44.1% 24.32 ± 4.04 Rabeprazole 20 mg BID Chen et al. 2010 Taiwan 200 8 weeks 42.6 63.36% 27.9 ± 2 Pantoprazole 40 mg QD 43.1 56.43% 28.2 ± 2.1 Pantoprazole 40 mg BID Vasiliadis et al. 2010 Greece 75 30 days 40.96 ± 11.98 70.8% 26.6 ± 0.97 Esomeprazole 40 mg BID 44.17 ± 11.18 75% 27.2 ± 0.87 Esomeprazole 40 mg QD 42.68 ± 11.34 72% 26.8 ± 1.17 Esomeprazole 40 mg QOD Galmiche et al. 2001 France 92 1 week 42.1 ± 14.3 63.64% N Rabeprazole 10 mg BID 39.4 ± 13.8 66.67% N Rabeprazole 20 mg QD 41.2 ± 14.2 73.91% N Omeprazole 20 mg QD 43.6 ± 11.3 52.17% N Placebo